“A Multicenter, Open Label, Phase 1 Study of the Safety, Tolerability, Systemic Exposure, Pharmacodynamics, and Treatment Effect of Calcipotriene Foam, 0.005% in Pediatric Subjects (Ages 2 to 11 Years) With Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine 4, no. 5 (September 2, 2020): s35. Accessed April 30, 2026. https://skin.dermsquared.com/skin/article/view/984.